Pronutria, a Cambridge, MA-based developer of medical foods and nutritional supplements, closed a $12.25m Series B financing.
The round, which has raised $23m to date, was led by Flagship VentureLabs, the innovation foundry of Flagship Ventures, and includes private investors.
The company intends to use the funds to advance the ProNutrein™ pipeline as well as develop additional candidates as medical foods and supplements.
Led by Robert Connelly, Chief Executive Officer, Pronutria just began two clinical trials evaluating its lead ProNutrein™ product candidates to identify and develop protein pharmaconutrients, protein nutrients identified in food with beneficial impact in many areas of human health, including muscle, metabolic and gastrointestinal health.
In preclinical models of muscle growth and thermogenesis, these candidates have demonstrated substantial efficacy.
The company expects to complete these trials by the end of the second quarter of 2014.
FinSMEs
15/02/2014
Related News
22/10/2013: Pronutria Launches with $10.8M in Series A Funding